Immune Checkpoint Blockade across the Cancer Care Continuum

5Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to—or in place of—standard front-line therapy. Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to—or in place of—standard front-line therapy.

Cite

CITATION STYLE

APA

Helmink, B. A., Gaudreau, P. O., & Wargo, J. A. (2018, June 19). Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity. Cell Press. https://doi.org/10.1016/j.immuni.2018.06.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free